Reduced efficacy of multiple doses of CpG-matured dendritic cell tumor vaccine in an experimental model

Arash Pourgholaminejad, Arezoo Jamali, Morteza Samadi-Foroushani, Afshin Amari, Reza Mirzaei, Bita Ansaripour, Nemat Khansari, Mohammad Reza Aghasadeghi, Babak Baban, Jamshid Hadjati

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

CpG motifs have been advanced as agents that stimulate the maturation of DCs for immunotherapy. The present study tested the hypothesis that multiple doses of CpG-matured DC vaccine would be efficacious for complete eradication of experimentally-induced tumor. Accordingly, WEHI164 cells were implanted subcutaneously in the flank of BALB/c mice. During DC culture, tumor lysate was added to immature DCs followed by addition of CpG or non-CpG control 4-6 h later. A total of three doses of CpG or non-CpG control-matured DCs were injected around tumors. The results showed that multiple doses of CpG-matured DCs led to considerable decrease in cytotoxicity of lymphocytes and significantly increased tumor growth rate compared to a single dose. Further, mice which received three doses of the vaccine also displayed significant FoxP3 in tumor tissue. In conclusion, multiple doses of CpG-matured DCs exhibited decreased anti-tumor immunity in association with increased expression of FoxP3.

Original languageEnglish (US)
Pages (from-to)360-364
Number of pages5
JournalCellular Immunology
Volume271
Issue number2
DOIs
StatePublished - 2011

Keywords

  • Cell therapy
  • FoxP3
  • Synthetic oligodeoxynucleotides
  • Tumor immunotherapy

ASJC Scopus subject areas

  • Immunology

Fingerprint

Dive into the research topics of 'Reduced efficacy of multiple doses of CpG-matured dendritic cell tumor vaccine in an experimental model'. Together they form a unique fingerprint.

Cite this